Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia

about

3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia.Reported direct aminopyridine effects on voltage-gated calcium channels is a high-dose pharmacological off-target effect of no clinical relevance

P2860

Q49561997-1EB0BEC4-5323-417D-A024-672721D157EC Q57471361-5D55C38F-39B0-4B68-B491-0BBDA0CFFA9E

P2860

Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia

Item

http://www.wikidata.org/entity/Q38721390

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Population Pharmacokinetics/Ph ...... With Lambert-Eaton Myasthenia

@en

type

Item

label

Population Pharmacokinetics/Ph ...... With Lambert-Eaton Myasthenia

@en

prefLabel

Population Pharmacokinetics/Ph ...... With Lambert-Eaton Myasthenia

@en

P1476

Population Pharmacokinetics/Ph ...... With Lambert-Eaton Myasthenia

@en

P2093

Charles Peloquin

http://www.w3.org/2001/XMLSchema#string

DAPPER Study Group

http://www.w3.org/2001/XMLSchema#string

David Jacobus

http://www.w3.org/2001/XMLSchema#string

Jeffrey T Guptill

http://www.w3.org/2001/XMLSchema#string

Kathy Aleš

http://www.w3.org/2001/XMLSchema#string

Laura Jacobus

http://www.w3.org/2001/XMLSchema#string

Michael Cohen-Wolkowiez

http://www.w3.org/2001/XMLSchema#string

Nilay Thakkar

http://www.w3.org/2001/XMLSchema#string

P2860

A web server for inferring the human N-acetyltransferase-2 (NAT2) enzymatic phenotype from NAT2 genotype

3,4-diaminopyridine. A potent new potassium channel blocker

PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Novel drug of choice in Eaton-Lambert syndrome.

Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome.

Identifying a cut-off point for normal mobility: a comparison of the timed 'up and go' test in community-dwelling and institutionalised elderly women.

Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine

Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies.

Pathogenic autoantibodies in the lambert-eaton myasthenic syndrome.

Prognostic validity of the Timed Up-and-Go test, a modified Get-Up-and-Go test, staff's global judgement and fall history in evaluating fall risk in residential care facilities.

P304

625-634

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PSP4.12218

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Daniel Gonzalez

P577

2017-06-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28623849

http://www.w3.org/2001/XMLSchema#string

P932

5613184

http://www.w3.org/2001/XMLSchema#string

Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia

about

P2860

P2860

Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932